Compare PAI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAI | DERM |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.2M | 135.3M |
| IPO Year | N/A | 2021 |
| Metric | PAI | DERM |
|---|---|---|
| Price | $12.13 | $6.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 18.9K | ★ 191.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | N/A | $39.72 |
| Revenue Next Year | N/A | $63.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $11.72 | $4.31 |
| 52 Week High | $13.22 | $9.56 |
| Indicator | PAI | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 58.45 |
| Support Level | $12.06 | $5.79 |
| Resistance Level | $12.35 | $6.59 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 59.57 | 77.27 |
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. Its primary investment objective is to seek a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. To a lesser extent, the fund also invests in privately placed debt securities and in certain equity securities. Capital appreciation is its secondary investment objective. The fund invests a majority of its net assets in fixed income securities that are rated in the Baa or BBB categories or above at the time of purchase by one or more Nationally Recognized Statistical Rating Organizations (NRSROs) or unrated securities of comparable quality at the time of purchase (as determined by the investment adviser).
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.